ProCE Banner Activity

Strategies for Patients With Treatment Experience

Video

Hear from expert faculty as they discuss questions about managing ART failure including guideline definitions and recommendations, the likelihood of failure with resistance with first-line ART regimens, drug‒drug interaction considerations, and more.

Released: July 24, 2023

Share

Faculty

Daniel R Kuritzkes

Daniel R Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Cristina Mussini

Cristina Mussini, MD

Full Professor of Infectious Diseases
Chief of the Department of Infectious Diseases
University of Modena and Reggio Emilia
Modena, Italy

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare

Disclosure

Primary Author

Daniel R Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD: consultant: AbbVie, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Roche, ViiV Healthcare; researcher: Gilead Sciences, Merck, ViiV Healthcare.

Cristina Mussini, MD

Full Professor of Infectious Diseases
Chief of the Department of Infectious Diseases
University of Modena and Reggio Emilia
Modena, Italy

Cristina Mussini, MD: consultant/advisor/speaker: Angelini, Janssen, MSD, Roche, ViiV; researcher: Gilead.